New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:26 EDTVRX, OMPIValeant price target raised to $80 from $70 at RBC Capital
RBC Capital increased its price target on Valeant (VRX) to reflect the Obagi (OMPI) acquisition, higher conviction levels for IDP-108 launch and an expected increase to 2013 guidance during the Q1 results conference call. The firm doesn't see the Obagi deal as transformational for Valeant but does expect it to generate at least $40M in synergies. RBC maintains an Outperform rating on Valeant.
News For VRX;OMPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTVRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use